MktsMarkets

Processa Pharmaceuticals, Inc.
NASDAQ: PCSAKey statistics
PCSA News
Stories mentioning PCSA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (3,331) | (3,702) | (3,489) | (3,951) | (2,847) | (2,734) | (3,425) | (3,082) |
| Interest Income | 14.00 | 13.00 | 40.00 | |||||
| Interest Expense | ||||||||
| Other Expense | 72.00 | |||||||
| Pretax Income | (3,377) | (2,834) | (3,010) | |||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,377) | (3,359) | (3,437) | (3,934) | (2,834) | (2,729) | (3,385) | (3,010) |
| Earnings Per Share (Basic) | (1.29) | (2.57) | (0.07) | (0.25) | (7.58) | (22.37) | (1.03) | (1.01) |
| Earnings Per Share (Diluted) | (1.29) | (2.57) | (0.07) | (0.25) | (7.58) | (22.37) | (1.03) | (1.01) |
| Weighted Average Shares Outstanding (Basic) | 2,623 | 1,309 | 47,526 | 15,569 | 374.00 | 122.00 | 3,276 | 2,983 |
| Weighted Average Shares Outstanding (Diluted) | 2,623 | 1,309 | 47,526 | 15,569 | 374.00 | 122.00 | 3,276 | 2,983 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PCSA
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) is a stock listed on the Nasdaq Stock Market under the ticker symbol PCSA. It last traded at $1.69 (Oct 16, 2026, 4:00 PM ET), up 0.6% on the day. That gives Processa Pharmaceuticals a market capitalisation of $4.7M.
Over the past 52 weeks PCSA has traded between $1.04 and $10.84.
For the quarter ended Mar 31, 2026 it reported a net loss of $3.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$3.4M |
| Dec 31, 2025 | — | -$3.4M |
| Sep 30, 2025 | — | -$3.4M |
| Jun 30, 2025 | — | -$3.9M |
From Processa Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…